$3080 | SAVE $420 | Single User
$6160 | SAVE $840 | Site License
$9240 | SAVE $1,260 | Enterprise License

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 23 Nov 2016 | 34758 | In Stock
Related Topics: Protein

Introduction

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H2 2016’, provides in depth analysis on Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted pipeline therapeutics.

The report provides comprehensive information on the Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)

- The report reviews Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects

- The report assesses Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 6

    List of Figures 7

    Introduction 8

    Global Markets Direct Report Coverage 8

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) Overview 9

    Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene. It is involved in initiation and maintenance of cell cycle exit during cell differentiation, prevents cell proliferation and regulates negatively cell differentiation. It is required during thymocyte development. It promotes the production of newborn neurons, probably by modulating G1 length, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. It prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation-activity.Therapeutics Development 9

    Therapeutics Development 10

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Products under Development by Stage of Development 10

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Products under Development by Therapy Area 11

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Products under Development by Indication 12

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Products Glance 14

    Late Stage Products 14

    Early Stage Products 15

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Products under Development by Companies 16

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Products under Development by Universities/Institutes 21

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Therapeutics Assessment 23

    Assessment by Monotherapy/Combination Products 23

    Assessment by Mechanism of Action 24

    Assessment by Route of Administration 25

    Assessment by Molecule Type 27

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Companies Involved in Therapeutics Development 29

    Beta Pharma Inc 29

    Eli Lilly and Company 30

    FLX Bio, Inc. 31

    G1 Therapeutics Inc 32

    Jiangsu Hengrui Medicine Co Ltd 33

    Novartis AG 34

    Onconova Therapeutics Inc 35

    Pfizer Inc 36

    Teijin Pharma Ltd 37

    ViroStatics srl 38

    XuanZhu Pharma Co Ltd 39

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Drug Profiles 40

    abemaciclib - Drug Profile 40

    Product Description 40

    Mechanism Of Action 40

    R&D Progress 40

    BPI-1178 - Drug Profile 45

    Product Description 45

    Mechanism Of Action 45

    R&D Progress 45

    FLX-925 - Drug Profile 46

    Product Description 46

    Mechanism Of Action 46

    R&D Progress 46

    G-1T28 - Drug Profile 48

    Product Description 48

    Mechanism Of Action 48

    R&D Progress 48

    G-1T38 - Drug Profile 50

    Product Description 50

    Mechanism Of Action 50

    R&D Progress 50

    GZ-381 - Drug Profile 51

    Product Description 51

    Mechanism Of Action 51

    R&D Progress 51

    MMD-37K - Drug Profile 52

    Product Description 52

    Mechanism Of Action 52

    R&D Progress 52

    ON-123300 - Drug Profile 53

    Product Description 53

    Mechanism Of Action 53

    R&D Progress 53

    palbociclib - Drug Profile 54

    Product Description 54

    Mechanism Of Action 54

    R&D Progress 54

    ribociclib succinate - Drug Profile 65

    Product Description 65

    Mechanism Of Action 65

    R&D Progress 65

    SHR-6390 - Drug Profile 70

    Product Description 70

    Mechanism Of Action 70

    R&D Progress 70

    Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile 71

    Product Description 71

    Mechanism Of Action 71

    R&D Progress 71

    Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile 72

    Product Description 72

    Mechanism Of Action 72

    R&D Progress 72

    Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile 73

    Product Description 73

    Mechanism Of Action 73

    R&D Progress 73

    Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile 74

    Product Description 74

    Mechanism Of Action 74

    R&D Progress 74

    Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers and Warts - Drug Profile 75

    Product Description 75

    Mechanism Of Action 75

    R&D Progress 75

    Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HSV Infections - Drug Profile 76

    Product Description 76

    Mechanism Of Action 76

    R&D Progress 76

    Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology - Drug Profile 77

    Product Description 77

    Mechanism Of Action 77

    R&D Progress 77

    Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile 78

    Product Description 78

    Mechanism Of Action 78

    R&D Progress 78

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Dormant Projects 79

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Discontinued Products 80

    Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Featured News & Press Releases 81

    Nov 16, 2016: PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer 81

    Nov 10, 2016: IBRANCE (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer 82

    Nov 01, 2016: Astex Achieves Milestone on US FDA Filing of New Drug Application (NDA) for LEE011 (Ribociclib) Plus Letrozole as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer 84

    Nov 01, 2016: Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer 84

    Oct 08, 2016: Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care 85

    Oct 05, 2016: Lilly Presents New Data on Abemaciclib At ESMO 2016 86

    Sep 16, 2016: Pfizer Receives Positive CHMP Opinion For IBRANCE (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe 87

    Aug 10, 2016: Lilly Provides Update on MONARCH 2 Phase 3 Trial of Abemaciclib 87

    Aug 03, 2016: Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer 88

    Jul 13, 2016: European breast cancer trial opens in Ireland 89

    Jul 06, 2016: Study Tests New Breast Cancer Drug In African American Women 90

    Jun 03, 2016: Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy 91

    May 31, 2016: Lilly Announces Webcast To Discuss Abemaciclib Data 92

    May 23, 2016: Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types 92

    May 18, 2016: Eli Lilly to Present final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer at ASCO 93

    Appendix 95

    Methodology 95

    Coverage 95

    Secondary Research 95

    Primary Research 95

    Expert Panel Validation 95

    Contact Us 95

    Disclaimer 96

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

34758 | GMDHC0685TDB

Number of Pages

96

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2018
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division ...
20 Nov 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H1 2017
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipel...
30 May 2017 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H1 2017
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division ...
30 May 2017 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Cyclin-Dependent Kinase 1 (CDK1) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Cyclin-Dependent Kinase 1 (CDK1) Inhibitors-Pipeline Insights, 2017”, report provid...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Cyclin-Dependent Kinase 2 (CDK2) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Cyclin-Dependent Kinase 2 (CDK2) Inhibitors-Pipeline Insights, 2017”, report provid...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Cyclin-Dependent Kinase 4 (CDK4) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Cyclin-Dependent Kinase 4 (CDK4) Inhibitors-Pipeline Insights, 2017”, report provid...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2016
Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Con...
23 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H2 2016
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2016
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Pipeline Review, H2 2016
Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Cat...
09 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...